MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol
The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
BCL2 family members are subject to regulation at multiple levels, providing checks on their ability to contribute to tumorigenesis. However, findings on post-translational BCL2 phosphorylation in different systems have been difficult to integrate. Another antiapoptotic family member, MCL1, exhibits a difference in electrophoretic mobility upon phosphorylation induced by an activator of PKC (12-O-tetradecanoylphorbol 13-acetate; TPA) versus agents that act on microtubules or protein phosphatases 1/2A. A multiple pathway model is now presented, which demonstrates that MCL1 can undergo distinct phosphorylation events - mediated through separate signaling processes and involving different target sites - in cells that remain viable in the presence of TPA versus cells destined to die upon exposure to taxol or okadaic acid. Specifically, TPA induces phosphorylation at a conserved extracellular signal-regulated kinase (ERK) site in the PEST region (Thr 163) and slows turnover of the normally rapidly degraded MCL1 protein; however, okadaic acid and taxol induce ERK-independent MCL1 phosphorylation at additional discrete sites. These findings add a new dimension to our understanding of the complex regulation of antiapoptotic BCL2 family members by demonstrating that, in addition to transcriptional and post-transcriptional regulation, MCL1 is subject to multiple, separate, post-translational phosphorylation events, produced in living versus dying cells at ERK-inducible versus ERK-indepe…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“MCL-1 phosphorylation at T163 decreased acutely upon trametinib treatment consistent with a loss of ERK phosphorylation59 and then rebounded at later time points coinciding with activation of JNK (Fig. S11A).”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [59]
In the citing paper
“ERK1/2 stabilise MCL1 through phosphorylation of T163 and indirectly through RSK-mediated inhibition of GSK39.”
From Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors (2019) · cites this paper as [9]
In the citing paper
“ERK-mediated phosphorylation of the MCL-1-PEST domain has been reported to limit MCL-1 degradation.”
From BCL-XL inhibition induces an FGFR4-mediated rescue response in colorectal cancer (2022) · cites this paper as Domina et al., 2004
In the citing paper
“Our data therefore suggest that the induction of MCL-1 protein upon A-1155463 treatment could be mediated by FGFR4-driven ERK signaling (Domina et al., 2004) (Figure 5C).”
From BCL-XL inhibition induces an FGFR4-mediated rescue response in colorectal cancer (2022) · cites this paper as Domina et al., 2004
Citations
Cites
Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability
Sears, R., Nuckolls, F., Haura, E., Taya, Y., Tamai, K., & Nevins, J. R. (2000) · Genes & Development · doi:10.1101/gad.836800 · Cited by 1,393 · cited 2×
“Since the degradation of a variety of other PEST proteins is affected by phosphorylation (Rechsteiner, 1990; Clurman et al., 1996; Chen et al., 2000; Gregory and Hann, 2000; Sears et al., 2000; Koepp et al., 2001), we wondered whether this might likewise be the case with MCL1.”
BackgroundCurrent Protocols in Protein Science
(2018) · Current Protocols in Protein Science · doi:10.1002/(issn)1934-3663 · Cited by 1,189
Ca 2+ -Induced Apoptosis Through Calcineurin Dephosphorylation of BAD
Wang, H.-G., Pathan, N., Ethell, I. M., Krajewski, S., Yamaguchi, Y., Shibasaki, F., McKeon, F., Bobo, T., Franke, T. F., & Reed, J. C. (1999) · Science · doi:10.1126/science.284.5412.339 · Cited by 1,132 · cited 2×
“This latter modification has been extensively characterized in the case of the proapoptotic family member BAD (Scheid et al., 1999; Wang et al., 1999; Harada et al., 2001).”
BackgroundTsujimoto, Y., & Croce, C. M. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.14.5214 · Cited by 1,106 · cited 1×
“Expression of such viability-regulating gene products is often aberrant in cancer, as exemplified by the BCL2 overexpression seen in follicular lymphoma (Tsujimoto and Croce, 1986).”
BackgroundYamamoto, K., Ichijo, H., & Korsmeyer, S. J. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.12.8469 · Cited by 1,003 · cited 4×
“Conversion of Ser 70 and/or Ser 87 to Ala similarly resulted in enhanced viability promotion in human Jurkat or mouse WEHI231 cells (Yamamoto et al., 1999).”
BackgroundMethodInfluentialMCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2.
Kozopas, K. M., Yang, T., Buchan, H. L., Zhou, P., & Craig, R. W. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3516 · Cited by 961 · cited 3×
“…and slows turnover of the MCL1 protein We focused first on further studies with TPA, since we have extensively examined the effects of this agent on MCL1 expression and phosphorylation (Kozopas et al., 1993; Yang et al., 1996; Zhou et al., 1997; Townsend et al., 1998, 1999; Domina et al., 2000).”
BackgroundSelf-citationGeneration of Destabilized Green Fluorescent Protein as a Transcription Reporter
Li, X., Zhao, X., Fang, Y., Jiang, X., Duong, T., Fan, C., Huang, C.-C., & Kain, S. R. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.52.34970 · Cited by 846 · cited 2×
“MCL1 turnover was assessed using standard methods (Li et al., 1998; Akgul et al., 2000; Gregory and Hann, 2000; Cuconati et al., 2003), by exposing cells to cycloheximide to inhibit protein synthesis (25 mg/ml) and monitoring loss of the existing MCL1 protein over time by Western blotting.”
MethodDevelopment and maintenance of B and T lymphocytes requires antiapoptotic MCL-1
Opferman, J. T., Letai, A., Beard, C., Sorcinelli, M. D., Ong, C. C., & Korsmeyer, S. J. (2003) · Nature · doi:10.1038/nature02067 · Cited by 801 · cited 1×
“A distinctive characteristic of MCL1 in these systems, as in differentiating cells like ML-1 cells, is its ability to act in a rapid but often shortterm fashion, under conditions of changing cell phenotype (Craig, 2002; Opferman et al., 2003).”
BackgroundPhosphorylation-Dependent Ubiquitination of Cyclin E by the SCF Fbw7 Ubiquitin Ligase
Koepp, D. M., Schaefer, L. K., Ye, X., Keyomarsi, K., Chu, C., Harper, J. W., & Elledge, S. J. (2001) · Science · doi:10.1126/science.1065203 · Cited by 762 · cited 1×
“Since the degradation of a variety of other PEST proteins is affected by phosphorylation (Rechsteiner, 1990; Clurman et al., 1996; Chen et al., 2000; Gregory and Hann, 2000; Sears et al., 2000; Koepp et al., 2001), we wondered whether this might likewise be the case with MCL1.”
BackgroundElimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation
Nijhawan, D., Fang, M., Traer, E., Zhong, Q., Gao, W., Du, F., & Wang, X. (2003) · Genes & Development · doi:10.1101/gad.1093903 · Cited by 591 · cited 1×
“Whatever the mechanism, the importance of MCL1 turnover in the control of cell viability has recently been brought to the fore by the demonstration that loss of MCL1 is an early step in apoptosis induced by DNA damage or by the viral E1A protein (Cuconati et al., 2003; Nijhawan et al., 2003).”
Background
Cited by
The extracellular signal-regulated kinase: Multiple substrates regulate diverse cellular functions
Yoon, S., & Seger, R. (2006) · Growth Factors · doi:10.1080/02699050500284218 · Cited by 1,273
ERK signalling: A master regulator of cell behaviour, life and fate
Lavoie, H., Gagnon, J., & Therrien, M. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0255-7 · Cited by 1,185
Maurer, U., Charvet, C., Wagman, A. S., Dejardin, E., & Green, D. R. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.02.009 · Cited by 881
“Interestingly, MCL-1 similarly shows increased stability when phosphorylated on threonine 163, which represents the GSK-3 priming phosphorylation in this protein (Domina et al., 2004).”
BackgroundSensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7
Wertz, I. E., Kusam, S., Lam, C., Okamoto, T., Sandoval, W., Anderson, D. J., Helgason, E., Ernst, J. A., Eby, M., Liu, J., et al. (2011) · Nature · doi:10.1038/nature09779 · Cited by 794
ERK1/2 MAP kinases in cell survival and apoptosis
Lu, Z., & Xu, S. (2006) · IUBMB Life · doi:10.1080/15216540600957438 · Cited by 648
“Mcl-1, an anti-apoptotic member of the Bcl-2 family, is phosphorylated at Thr163 by ERK1/2, thus increasing its stability and enhancing its anti-apoptotic activity ( 67 ).”
BackgroundDeubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival
Schwickart, M., Huang, X., Lill, J. R., Liu, J., Ferrando, R., French, D. M., Maecker, H., O’Rourke, K., Bazan, F., Eastham-Anderson, J., et al. (2010) · Nature · doi:10.1038/nature08646 · Cited by 628
RAF-MEK-ERK pathway in cancer evolution and treatment
Ullah, R., Yin, Q., Snell, A. H., & Wan, L. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.05.010 · Cited by 553
Steelman, L. S., Chappell, W. H., Abrams, S. L., Kempf, C. R., Long, J., Laidler, P., Mijatovic, S., Maksimovic-Ivanic, D., Stivala, F., Mazzarino, M. C., et al. (2011) · Aging · doi:10.18632/aging.100296 · Cited by 553
“Akt and mTOR are linked to each other via positive and negative regulatory circuits, which restrain their simultaneous hyperactivation through a mechanism involving p70 and PI3K [4,19,35,44,48-55].”
BackgroundMcl‐1; the molecular regulation of protein function
Thomas, L. W., Lam, C., & Edwards, S. W. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.05.061 · Cited by 538
Tumour cell survival signalling by the ERK1/2 pathway
Balmanno, K., & Cook, S. J. (2009) · Cell Death & Differentiation · doi:10.1038/cdd.2008.148 · Cited by 484
Perciavalle, R. M., Stewart, D. P., Koss, B., Lynch, J., Milasta, S., Bathina, M., Temirov, J., Cleland, M. M., Pelletier, S., Schuetz, J. D., et al. (2012) · Nature Cell Biology · doi:10.1038/ncb2488 · Cited by 410
Regulation of the Intrinsic Apoptosis Pathway by Reactive Oxygen Species
Wu, C.-C., & Bratton, S. B. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4905 · Cited by 408
“…have established roles in the regulation of many pro-and antiapoptotic BCL-2 family members, often converging upon them and regulating their expression or function in highly complex ways, as in the case of MCL-1 regulation by ERKs, JNKs, and glycogen synthase kinase-3 b (GSK-3 b ) (32, 53, 83, 86).”
Ding, Q., He, X., Hsu, J.-M., Xia, W., Chen, C.-T., Li, L.-Y., Lee, D.-F., Liu, J.-C., Zhong, Q., Wang, X., et al. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00620-06 · Cited by 393
“2D), whereas Erk phosphorylated Mcl-1 strongly only at the 163T residue, consistent with data from a previous report (15) and suggesting that phosphosphorylation at the 163T residue may be mediated mostly by Erk.”
BackgroundDavies, B. R., Logie, A., McKay, J. S., Martin, P., Steele, S., Jenkins, R., Cockerill, M., Cartlidge, S., & Smith, P. D. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0231 · Cited by 387
Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia
Steelman, L. S., Abrams, S. L., Whelan, J., Bertrand, F. E., Ludwig, D. E., Bäsecke, J., Libra, M., Stivala, F., Milella, M., Tafuri, A., et al. (2008) · Leukemia · doi:10.1038/leu.2008.26 · Cited by 385
Harley, M. E., Allan, L. A., Sanderson, H. S., & Clarke, P. R. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.112 · Cited by 353
“Thr92 is phosphorylated by ERK in vitro (Ding et al, 2008), but its phosphorylation in cells has not been described earlier.”
BackgroundInfluentialHow the Bcl-2 family of proteins interact to regulate apoptosis
van Delft, M. F., & Huang, D. C. (2006) · Cell Research · doi:10.1038/sj.cr.7310028 · Cited by 335
Mcl-1 is a potential therapeutic target in multiple types of cancer
Akgul, C. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8637-6 · Cited by 329
Pan, R., Ruvolo, V., Mu, H., Leverson, J. D., Nichols, G., Reed, J. C., Konopleva, M., & Andreeff, M. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.11.003 · Cited by 300
“This finding agrees with previous reports that pERK phosphorylates Mcl-1 at T163 (Domina et al., 2004; Gores and Kaufmann, 2012).”
ResultYu, C., Bruzek, L. M., Meng, X. W., Gores, G. J., Carter, C. A., Kaufmann, S. H., & Adjei, A. A. (2005) · Oncogene · doi:10.1038/sj.onc.1208841 · Cited by 277
“Since Mcl-1 is phosphorylated on a number of different residues in response to a variety of stimuli (Domina et al., 2000, 2004; Inoshita et al., 2002), turnover of this short-lived antiapoptotic protein is likely subject to regulation by a number of different signaling pathways.”
BackgroundInfluentialERK: A Key Player in the Pathophysiology of Cardiac Hypertrophy
Gallo, S., Vitacolonna, A., Bonzano, A., Comoglio, P., & Crepaldi, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092164 · Cited by 264
Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy
Steelman, L. S., Franklin, R. A., Abrams, S. L., Chappell, W., Kempf, C. R., Bäsecke, J., Stivala, F., Donia, M., Fagone, P., Nicoletti, F., et al. (2011) · Leukemia · doi:10.1038/leu.2011.66 · Cited by 261
Evidence That Ser87 of BimEL Is Phosphorylated by Akt and Regulates BimEL Apoptotic Function
Qi, X.-J., Wildey, G. M., & Howe, P. H. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m505546200 · Cited by 234
Kobayashi, S., Werneburg, N. W., Bronk, S. F., Kaufmann, S. H., & Gores, G. J. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.010 · Cited by 226
Regulation of DNA fragmentation: the role of caspases and phosphorylation
Kitazumi, I., & Tsukahara, M. (2011) · The FEBS Journal · doi:10.1111/j.1742-4658.2010.07975.x · Cited by 223
Extracellular-Regulated Kinases: Signaling From Ras to ERK Substrates to Control Biological Outcomes
(2018) · Advances in Cancer Research · doi:10.1016/bs.acr.2018.02.004 · Cited by 215
The MEK/ERK Network as a Therapeutic Target in Human Cancer
Barbosa, R., Acevedo, L. A., & Marmorstein, R. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0687 · Cited by 210
“For example, ERK phosphorylation has been shown to inhibit the proapoptotic Bim protein or stabilize the antiapoptotic protein Mcl-1 (57, 58).”
BackgroundTargeting Mcl-1 for the therapy of cancer
Quinn, B. A., Dash, R., Azab, B., Sarkar, S., Das, S. K., Kumar, S., Oyesanya, R. A., Dasgupta, S., Dent, P., Grant, S., et al. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.609167 · Cited by 202
“Thr(163) can be phosphorylated by extracellular signal-regulated kinase (ERK) leading to the increased half-life of the protein [15].”
BackgroundDing, Q., Huo, L., Yang, J.-Y., Xia, W., Wei, Y., Liao, Y., Chang, C.-J., Yang, Y., Lai, C.-C., Lee, D.-F., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0579 · Cited by 199
“It is also known that Erk phosphorylates Mcl-1 and up-regulates its expression (36), and that the phosphorylation site of Erk is pSer/Thr-Pro, which is also the consensus motif recognized by Pin1.”
BackgroundGSK-3 – at the crossroads of cell death and survival
Maurer, U., Preiss, F., Brauns-Schubert, P., Schlicher, L., & Charvet, C. (2014) · Journal of Cell Science · doi:10.1242/jcs.138057 · Cited by 188
“Intriguingly, ERK-mediated phosphorylation of T163 (the GSK-3-priming site in human Mcl-1) results in Mcl-1 stabilization (Domina et al., 2004) in a”
BackgroundMcl-1 Ubiquitination: Unique Regulation of an Essential Survival Protein
Mojsa, B., Lassot, I., & Desagher, S. (2014) · Cells · doi:10.3390/cells3020418 · Cited by 181
“Although the studies mentioned above all showed that Thr163 phosphorylation promotes Mcl-1 degradation [87–92], others reported that phosphorylation by ERK at the same site stabilizes Mcl-1 [48,68–70].”
BackgroundMitogen-activated protein kinases in hepatocellular carcinoma development
Min, L., He, B., & Hui, L. (2011) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2010.10.011 · Cited by 178
ERK1/2‐dependent phosphorylation of BimEL promotes its rapid dissociation from Mcl‐1 and Bcl‐xL
Ewings, K. E., Hadfield‐Moorhouse, K., Wiggins, C. M., Wickenden, J. A., Balmanno, K., Gilley, R., Degenhardt, K., White, E., & Cook, S. J. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601723 · Cited by 176
“…phosphorylation of BimEL is required for dissociation of the Bim/Mcl-1 and Bim/Bcl-xL complex The dissociation of BimEL from Mcl-1 could be due to ERK1/ 2-dependent phosphorylation of BimEL (Luciano et al, 2003; Ley et al, 2004; Marani et al, 2004), Mcl-1 (Domina et al, 2004) or both.”
BackgroundApoptosis in Cancer Biology and Therapy
Moyer, A., Tanaka, K., & Cheng, E. H. (2025) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-051222-115023 · Cited by 173
Ma, J., Zhao, S., Qiao, X., Knight, T., Edwards, H., Polin, L., Kushner, J., Dzinic, S. H., White, K., Wang, G., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0832 · Cited by 173
“Because phosphorylation of Mcl-1 at T163 has been shown to stabilize Mcl-1 by prolonging its half-life (29), we looked at phosphorylation of Mcl-1 postmidostaurin treatment.”
BackgroundBasu, A. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107943 · Cited by 171
Control of cell death and mitochondrial fission by ERK 1/2 MAP kinase signalling
Cook, S. J., Stuart, K., Gilley, R., & Sale, M. J. (2017) · The FEBS Journal · doi:10.1111/febs.14122 · Cited by 170
Babon, J. J., McManus, E. J., Yao, S., DeSouza, D. P., Mielke, L. A., Sprigg, N. S., Willson, T. A., Hilton, D. J., Nicola, N. A., Baca, M., et al. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.024 · Cited by 163
Saga of Mcl-1: regulation from transcription to degradation
Senichkin, V. V., Streletskaia, A. Y., Gorbunova, A. S., Zhivotovsky, B., & Kopeina, G. S. (2020) · Cell Death & Differentiation · doi:10.1038/s41418-019-0486-3 · Cited by 155
“Extracellular signal-regulated kinase (ERK)-mediated phosphorylation of Thr163 (probably in conjunction with phosphorylation of Thr92) results in the increased stability and antiapoptotic activity of Mcl-1 [54, 55].”
BackgroundDoi, K., Li, R., Sung, S.-S., Wu, H., Liu, Y., Manieri, W., Krishnegowda, G., Awwad, A., Dewey, A., Liu, X., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.334532 · Cited by 158
“It has been demonstrated that ERK-mediated phosphorylation of Mcl-1 at Thr(163) prolongs the half-life of Mcl-1 (42), whereas phosphorylation of Ser(159) by GSK3 leads to increased ubiquitination and degradation ofMcl-1 (33).”
BackgroundShi, P., Oh, Y.-T., Deng, L., Zhang, G., Qian, G., Zhang, S., Ren, H., Wu, G., Legendre, B., Anderson, E., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1574 · Cited by 142
Konopleva, M., Milella, M., Ruvolo, P., Watts, J. C., Ricciardi, M. R., Korchin, B., McQueen, T., Bornmann, W., Tsao, T., Bergamo, P., et al. (2012) · Leukemia · doi:10.1038/leu.2011.287 · Cited by 139
“22 However, the specific isoform that dephosphorylates the protein is currently unknown.”
RetractedAkt as a therapeutic target in cancer
Steelman, L. S., Stadelman, K. M., Chappell, W. H., Horn, S., Bäsecke, J., Cervello, M., Nicoletti, F., Libra, M., Stivala, F., Martelli, A. M., et al. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.9.1139 · Cited by 140
Mcl-1 Integrates the Opposing Actions of Signaling Pathways That Mediate Survival and Apoptosis
Morel, C., Carlson, S. M., White, F. M., & Davis, R. J. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00279-09 · Cited by 143
“Phosphorylation on Ser121 and Thr-163 may inhibit the antiapoptotic activity of hMcl-1 (15), and phosphorylation on Thr-163 may increase hMcl-1 protein stability (9).”
BackgroundMelanoma: Molecular pathogenesis and emerging target therapies (Review)
Libra (2009) · International Journal of Oncology · doi:10.3892/ijo_00000277 · Cited by 136
“Activated ERK translocate to the nucleus and phosphorylate several nuclear transcription factors (Elk-1, Myc, CREB, Fos and others) which bind promoters of many genes, including growth factor and cytokine genes that are important for stimulating the cellular proliferation, differentiation, and survival of multiple cel…”
Mcl-1 Is Required for Melanoma Cell Resistance to Anoikis
Boisvert-Adamo, K., Longmate, W., Abel, E. V., & Aplin, A. E. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0358 · Cited by 127
“By contrast, phosphorylation of Thr(163) in response to ERK1/2 activation inhibits the proteasomal turnover of Mcl-1 (23).”
Ubiquitin-Independent Degradation of Antiapoptotic MCL-1
Stewart, D. P., Koss, B. S., Bathina, M., Perciavalle, R. M., Bisanz, K. M., & Opferman, J. T. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.01266-09 · Cited by 130
“Denatured samples were resolved by SDS-PAGE and immunoblotting.”
BackgroundInfluentialSerine 64 Phosphorylation Enhances the Antiapoptotic Function of Mcl-1
Kobayashi, S., Lee, S.-H., Meng, X. W., Mott, J. L., Bronk, S. F., Werneburg, N. W., Craig, R. W., Kaufmann, S. H., & Gores, G. J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610010200 · Cited by 117
Self-citationA pivotal role for Mcl-1 in Bortezomib-induced apoptosis
Podar, K., Gouill, S. L., Zhang, J., Opferman, J. T., Zorn, E., Tai, Y., Hideshima, T., Amiot, M., Chauhan, D., Harousseau, J., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210679 · Cited by 129
“Taxol-triggered ERK-independent Mcl-1 phosphorylation promotes cell death, whereas 12-O-tetradecanoyl-phorbol-13-acetate (TPA)triggered ERK-dependent Mcl-1 phosphorylation promotes cell viability via slowing the cell cycle and reducing Mcl-1 turnover (Domina et al., 2000, 2004).”
BackgroundMazumder, S., Choudhary, G. S., Al-harbi, S., & Almasan, A. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-4106 · Cited by 126
“It has been reported that Mcl-1 phosphorylation also regulates Mcl-1 protein stability, with Thr-163Mcl-1 phosphorylation by extracellular signal–regulated kinases (Erk) extending its half-life (20).”
Zhao, M., Ma, J., Zhu, H., Zhang, X., Du, Z., Xu, Y.-J., & Yu, X.-D. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-104 · Cited by 121
“These survival signals are important for initiating transcription of Mcl-1 and other antiapoptotic proteins and for maintaining their stability [42].”
BackgroundBettayeb, K., Tirado, Ò. M., Marionneau‐Lambot, S., Ferandin, Y., Lozach, O., Morris, J. C., Mateo‐Lozano, S., Drueckes, P., Schächtele, C., Kubbutat, M. H. G., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1826 · Cited by 134
Holt, S. V., Logié, A., Odedra, R., Heier, A., Heaton, S. P., Alferez, D., Davies, B. R., Wilkinson, R. W., & Smith, P. D. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.8 · Cited by 112
“Furthermore, active ERK can enhance the activity of anti-apoptotic proteins including Bcl-2 and Mcl-1 (Deng et al, 2000; Domina et al, 2004).”
BackgroundConstitutive ERK MAPK Activity Regulates Macrophage ATP Production and Mitochondrial Integrity
Monick, M. M., Powers, L. S., Barrett, C. W., Hinde, S., Ashare, A., Groskreutz, D. J., Nyunoya, T., Coleman, M., Spitz, D. R., & Hunninghake, G. W. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.11.7485 · Cited by 110
Rahmani, M., Aust, M. M., Attkisson, E., Williams, D. C., Ferreira‐Gonzalez, A., & Grant, S. (2012) · Blood · doi:10.1182/blood-2011-09-378141 · Cited by 116
Apigenin Sensitizes Colon Cancer Cells to Antitumor Activity of ABT-263
Shao, H., Jing, K., Mahmoud, E., Huang, H., Fang, X., & Yu, C. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0066 · Cited by 110
“As reported previously, ERK activation induces Mcl-1 phosphorylation at Threonine 163 which stabilizes Mcl-1 protein and lowers its turnover (40).”
BackgroundCross, A. L., Moots, R. J., & Edwards, S. W. (2007) · Blood · doi:10.1182/blood-2007-05-087833 · Cited by 103
Targeting MAPK pathway in melanoma therapy
Cheng, Y., Zhang, G., & Li, G. (2013) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9433-9 · Cited by 116
Activation of ATF4 mediates unwanted Mcl-1 accumulation by proteasome inhibition
Hu, J., Dang, N., Menu, E., Bryune, E. D., Xu, D., Camp, B. V., Valckenborgh, E. V., & Vanderkerken, K. (2011) · Blood · doi:10.1182/blood-2011-07-366492 · Cited by 105
Development of Mcl-1 inhibitors for cancer therapy
Negi, A., & Murphy, P. V. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.113038 · Cited by 91
Neutrophil apoptosis in rheumatoid arthritis is regulated by local oxygen tensions within joints
Cross, A. L., Barnes, T. C., Bucknall, R. C., Edwards, S. W., & Moots, R. J. (2006) · Journal of Leukocyte Biology · doi:10.1189/jlb.0306178 · Cited by 96
“However, cytokines such as GM-CSF can increase cellular levels of Mcl-1 by stabilizing the protein via Akt-Erk-mediated phosphorylation [61] and slowing its rate of turnover [26, 62].”
BackgroundKodama, Y., Taura, K., Miura, K., Schnabl, B., Osawa, Y., & Brenner, D. A. (2009) · Gastroenterology · doi:10.1053/j.gastro.2008.12.064 · Cited by 110
Opferman, J. T. (2006) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401978 · Cited by 95
Dikovskaya, D., Cole, J. J., Mason, S. M., Nixon, C., Karim, S. A., McGarry, L., Clark, W., Hewitt, R. N., Sammons, M. A., Zhu, J., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.07.055 · Cited by 89
“Since activated ERK is known to stabilize Mcl1 protein (Ding et al., 2008; Domina et al., 2004), we asked whether activated Ras increases Mcl1 protein stability.”
BackgroundTargeting the RAF/MEK/ERK, PI3K/AKT and P53 pathways in hematopoietic drug resistance
McCubrey, J. A., Steelman, L. S., Franklin, R. A., Abrams, S. L., Chappell, W. H., Wong, E. W. T., Lehmann, B. D., Terrian, D. M., Bäsecke, J., Stivala, F., et al. (2007) · Advances in Enzyme Regulation · doi:10.1016/j.advenzreg.2006.12.013 · Cited by 97
“Bax and Bak are then able to induce apoptosis.”
InfluentialWang, R., Xia, L., Gabrilove, J., Waxman, S., & Jing, Y. (2013) · Leukemia · doi:10.1038/leu.2012.180 · Cited by 85
“It has been found that Mcl-1 phosphorylation at the Thr163 site by ERK leads to a prolonged Mcl-1 half-life by preventing its degradation (26).”
BackgroundFibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells
Fedorenko, I. V., Abel, E. V., Koomen, J. M., Fang, B., Wood, E. R., Chen, Y. A., Fisher, K. J., Iyengar, S., Dahlman, K. B., Wargo, J. A., et al. (2016) · Oncogene · doi:10.1038/onc.2015.188 · Cited by 85
Wang, B., Ni, Z., Dai, X., Qin, L., Li, X., Xu, L., Lian, J., & He, F. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-98 · Cited by 88
“Mcl-1 can be phosphorylated by ERK at its Thr(163) site, which prolongs the half life of this protein [35].”
BackgroundThe downregulation of Mcl-1 via USP9X inhibition sensitizes solid tumors to Bcl-xl inhibition
Peddaboina, C. S., Jupiter, D. C., Fletcher, S., Yap, J. L., Rai, A., Tobin, R. P., Jiang, W., Rascoe, P. A., Rogers, M. K. N., Smythe, W. R., et al. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-541 · Cited by 82
“Mcl-1 can be phosphorylated in its PEST region, and thus stabilized, upon ERK activation [16].”
BackgroundRahmani, M., Anderson, A., Habibi, J. R., Crabtree, T. R., Mayo, M., Harada, H., Ferreira-Gonzalez, A., Dent, P., & Grant, S. (2009) · Blood · doi:10.1182/blood-2008-09-177881 · Cited by 80
Tan, N., Wong, M., Nannini, M. A., Hong, R., Lee, L. B., Price, S., Williams, K., Savy, P. P., Yue, P., Sampath, D., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0949 · Cited by 80
“Activation of ERK1/2 is reported to stabilize the antiapoptotic protein,MCL1 (17).”
BackgroundSale, M. J., Minihane, E., Monks, N. R., Gilley, R., Richards, F. M., Schifferli, K. P., Andersen, C. L., Davies, E. J., Vicente, M. A., Ozono, E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12409-w · Cited by 80
Elkholi, R., Renault, T. T., Serasinghe, M. N., & Chipuk, J. E. (2014) · Cancer & Metabolism · doi:10.1186/2049-3002-2-16 · Cited by 88
“MCL-1 through phosphorylation [54,55].”
Boiani, M., Daniel, C. K., Liu, X., Hogarty, M. D., & Marnett, L. J. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.414177 · Cited by 83
Chetoui, N., Sylla, K., Gagnon-Houde, J.-V., Alcaïde‐Loridan, C., Charron, D. J., Al‐Daccak, R., & Aoudjit, F. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0080 · Cited by 80
“Mcl-1 protein is tightly regulated by the proteasome pathway (32-34) and has been shown to be phosphorylated by ERK, resulting in protein stabilization and protection from proteasome degradation (68).”
BackgroundRole of Ku70 in deubiquitination of Mcl-1 and suppression of apoptosis
Wang, B., Xie, M., Li, R., Owonikoko, T. K., Ramalingam, S. S., Khuri, F. R., Curran, W. J., Wang, Y., & Deng, X. (2014) · Cell Death and Differentiation · doi:10.1038/cdd.2014.42 · Cited by 74
“Mcl-1 contains a PEST sequence that can act as a transferrable degradation signal.(6,38) The expression level of Mcl-1 is tightly regulated by ubiquitinating (that is, Mule, FBW7 and b-TrCP)(9,10,39) and deubiquitinating (USP9X) enzymes.”
BackgroundInfluentialChoi, Y. B., & Harhaj, E. W. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004458 · Cited by 75
Tunquist, B. J., Woessner, R. D., & Walker, D. H. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0033 · Cited by 70
“In addition, Mcl-1 becomes phosphorylated on sites within its PEST region in response to treatment with phorbol ester, oxidative stress, cytokine withdrawal, and microtubule-damaging agents, which affects its overall stability (20, 21).”
BackgroundOpposite Regulation of Oligodendrocyte Apoptosis by JNK3 and Pin1 after Spinal Cord Injury
Li, Q. M., Tep, C., Yune, T. Y., Zhou, X. Z., Uchida, T., Lu, K. P., & Yoon, S. O. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2478-07.2007 · Cited by 71
“It was shown in culture that extracellular signal-regulated kinase (ERK) phosphorylates Mcl-1 at T 163P in the basal state (Domina et al., 2004) and JNK phosphorylates Mcl-1 at S 121 and T 163 in response to H2O2 treatment (Inoshita et al., 2002).”
BackgroundResultRegulation of heat-induced apoptosis by Mcl-1 degradation and its inhibition by Hsp70
Stankiewicz, A. R., Livingstone, A. M., Mohseni, N., & Mosser, D. D. (2009) · Cell Death and Differentiation · doi:10.1038/cdd.2008.189 · Cited by 79
Seo, S. U., Kim, T., Kim, D., Min, K., & Kwon, T. K. (2017) · Redox Biology · doi:10.1016/j.redox.2017.07.017 · Cited by 72
Karpel‐Massler, G., Bâ, M., Shu, C., Halatsch, M., Westhoff, M., Bruce, J. N., Canoll, P., & Siegelin, M. D. (2015) · Oncotarget · doi:10.18632/oncotarget.5505 · Cited by 71
Programming cancer cells for high expression levels of Mcl1
Ertel, F., Nguyen, M., Roulston, A., & Shore, G. C. (2013) · EMBO Reports · doi:10.1038/embor.2013.20 · Cited by 75
Li, X., Su, Y., Madlambayan, G. J., Edwards, H. J., Polin, L., Kushner, J., Dzinic, S. H., White, K., Ma, J., Knight, T. E., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.201343 · Cited by 67
Expression and Function of Bcl-2 Proteins in Melanoma
Eberle, J., & Hossini, A. M. (2008) · Current Genomics · doi:10.2174/138920208785699571 · Cited by 72
“Thus Mcl-1 is characterized by an only short half-life due to its degradation through the proteasome pathway, which can be slowed down by phosphorylation through ERK [87].”
BackgroundInfluentialDeubiquitinase USP9x Confers Radioresistance through Stabilization of Mcl-1
Trivigno, D., Eßmann, F., Huber, S. M., & Rudner, J. (2012) · Neoplasia · doi:10.1593/neo.12598 · Cited by 69
“Whereas phosphorylation by extracellular regulated kinases 1 and 2 (ERK1/2) at threonine 163 slows Mcl-1 protein turnover, phosphorylation at serine 159 by glycogen synthase kinase-3β (GSK-3β) targets Mcl-1 for ubiquitylation and proteasomal degradation [12,14].”
Fofaria, N. M., Frederick, D. T., Sullivan, R. J., Flaherty, K. T., & Srivastava, S. K. (2015) · Oncotarget · doi:10.18632/oncotarget.5755 · Cited by 62
HIV/SIV Infection Primes Monocytes and Dendritic Cells for Apoptosis
Laforge, M., Campillo-Gimenez, L., Monceaux, V., Cumont, M., Hurtrel, B., Corbeil, J., Zaunders, J., Elbim, C., & Estaquier, J. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002087 · Cited by 71
“This phosphorylated form undergoes accelerated degradation [81,83].”
BackgroundProteinase-activated Receptor 2 (PAR2) Decreases Apoptosis in Colonic Epithelial Cells
Iablokov, V., Hirota, C. L., Peplowski, M. A., Ramachandran, R., Mihara, K., Hollenberg, M. D., & MacNaughton, W. K. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.610485 · Cited by 68
“Furthermore, MCL-1 has been reported to be stabilized by ERK1/2-dependent phosphorylation (58).”
BackgroundChu, R., Terrano, D. T., & Chambers, T. C. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.10.008 · Cited by 65
Endoplasmic reticulum stress-induced cell death mediated by the proteasome
Egger, L., Madden, D. T., Rhême, C., Rao, R. V., & Bredesen, D. E. (2007) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402125 · Cited by 64
Critical role of anti-apoptotic Bcl-2 protein phosphorylation in mitotic death
Eichhorn, J. M., Sakurikar, N., Alford, S. E., Chu, R., & Chambers, T. C. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.360 · Cited by 64
“Similarly, paclitaxel induced a complex pattern of Mcl-1 phosphorylation in Burkitt lymphoma cells, as determined by thermolysin digestion and 2D-phosphopeptide mapping.(31) Thus, there appears to be many additional phosphorylation sites in Mcl-1 associated with mitotic arrest yet to be identified, and a phosphorylati…”
Intersection of mitochondrial fission and fusion machinery with apoptotic pathways: Role of Mcl‐1
Morciano, G., Pedriali, G., Sbano, L., Iannitti, T., Giorgi, C., & Pinton, P. (2016) · Biology of the Cell · doi:10.1111/boc.201600019 · Cited by 64
“Depending on which serine or threonine residue is phosphorylated, it will lead to an opposite consequence, that is protein stabilisation or degradation (Inoshita et al., 2002; Domina et al., 2004).”
BackgroundMEK inhibitors as a chemotherapeutic intervention in multiple myeloma
Chang-Yew Leow, C., Gerondakis, S., & Spencer, A. (2013) · Blood Cancer Journal · doi:10.1038/bcj.2013.1 · Cited by 62
Transcriptomic profiles of aging in purified human immune cells
Reynolds, L. M., Ding, J., Taylor, J. R., Lohman, K., Soranzo, N., de la Fuente, A., Liu, T. F., Johnson, C., Barr, R. G., Register, T. C., et al. (2015) · BMC Genomics · doi:10.1186/s12864-015-1522-4 · Cited by 62
“These multiple bands are thought to occur for a variety of reasons, including: an alternative initiation site [74], alternative RNA splicing [75], serine/threonine phosphorylation [76,77], and perhaps most notably, and proteolytic cleavage of the Nterminus [74,78,79].”
BackgroundZhang, W., Borthakur, G. M., Chen, G., Chen, Y., Mu, H., Ruvolo, V. R., Nomoto, K., Zhao, N., Konopleva, M. Y., & Andreeff, M. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1580 · Cited by 63
“In addition, the activation of MAPK signaling has been reported to promote expression of anti-apoptotic Mcl-1 and to stabilize the protein (40, 41), which has a very short half-life (42).”
BackgroundNica, A. F., Tsao, C. C., Watt, J. C., Jiffar, T., Kurinna, S. M., Jurasz, P., Konopleva, M. Y., Andreeff, M., Radomski, M. W., & Ruvolo, P. P. (2008) · Cell Cycle · doi:10.4161/cc.7.21.6894 · Cited by 64
Salerni, B. L., Bates, D. J. P., Albershardt, T. C., Lowrey, C. H., & Eastman, A. R. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0028 · Cited by 63
Dual modulation of MCL-1 and mTOR determines the response to sunitinib
Elgendy, M., Abdel-Aziz, A. K., Renne, S. L., Bornaghi, V., Procopio, G., Colecchia, M., Kanesvaran, R., Toh, C. K., Bossi, D., Pallavicini, I., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci84386 · Cited by 57
Regulation of Ubiquitination-Mediated Protein Degradation by Survival Kinases in Cancer
Yamaguchi, H., Hsu, J. L., & Hung, M. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00015 · Cited by 65
“In addition to GSK3β, it has been show that ERK phosphorylates Mcl-1 at T92 and T163 (Domina et al., 2004; Ding et al., 2008).”
Background
Metadata
- Authors
- Domina, A. M., Vrana, J. A., Gregory, M. A., Hann, S. R., & Craig, R. W.
- Affiliations
- Dartmouth College (US)
- Vanderbilt University (US)
- Corresponding author
- Craig, Ruth W
- Venue
- Oncogene
- Published
- 2004-06-07
- Volume
- 23
- Issue
- 31
- Pages
- 5301-5315
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2041230280
- Cited by
- 327
- References
- 58
- Citations by year
- 2026: 7 · 2025: 8 · 2024: 6 · 2023: 15 · 2022: 13 · 2021: 24 · 2020: 10 · 2019: 16 · 2018: 9 · 2017: 15 · 2016: 14 · 2015: 16 · 2014: 29 · 2013: 26 · 2012: 25
- FWCI
- 3.68
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Hitchcock Foundation
- National Cancer Institute (R01-CA57359, R01CA057359)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- Mcl-1, protein phosphorylation, ERK signaling, protein stabilization, Bcl-2 family proteins, anti-apoptotic proteins, okadaic acid, paclitaxel, microtubule stabilization, protein phosphatase 2A, phorbol myristate acetate, post-translational regulation, apoptosis
- MeSH terms
- Amino Acid Sequence, Animals, Antineoplastic Agents, Phytogenic, Binding Sites, Carcinogens, Cell Survival, Dogs, Dose-Response Relationship, Drug, Enzyme Activation, Enzyme Inhibitors, Cricetinae, Humans, Molecular Sequence Data, Neoplasm Proteins, Peptide Mapping, Phosphorylation, Precipitin Tests, Protein Kinase C, Tetradecanoylphorbol Acetate, Threonine, Time Factors, Transfection, Signal Transduction, CHO Cells, Apoptosis, Paclitaxel, Protein Structure, Tertiary, Proto-Oncogene Proteins c-bcl-2, Okadaic Acid, Mitogen-Activated Protein Kinases, MAP Kinase Signaling System, Cell Line, Tumor, Mice, Myeloid Cell Leukemia Sequence 1 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.